Back to Freestone Grove Partners LP Freestone Grove Partners LP

PTGXPTGX

2 quarters

Position history for Freestone Grove Partners LPFreestone Grove Partners LP's holdings in PROTAGONIST THERAPEUTICS INC

No. Freestone Grove Partners exited its PTGX (Protagonist Therapeutics) position in Q1 2025. Its Q4 2024 13F listed 6,644 shares worth $256,458. Freestone Grove Partners already held PTGX in its Q4 2024 13F, the earliest on record, and held it in 1 quarterly 13F filing.

Final Value

$0

Final Shares

0

Total Value Change

-$256,458

Total Shares Change

-6,644

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2025-Q1
Latest
Exited
0
-100.0%
$00.0%$48.36
0
2024-Q4
First report
6,644
—
$256,4580.0%$38.60
0

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used